跳至主要内容
临床试验/NCT05099835
NCT05099835已完成不适用

Ultrasound-Guided Stellate Ganglion Block With Botulinum Toxin Versus Steroid in Refractory Bell's Palsy

Assiut University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
1
主要终点
Change from Baseline House-Brackmann

研究概览

简要总结

the local stellate ganglion block with bupivacaine and corticosteroid treatment for acute peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local therapy may be necessary and some time may ve ineffective. Our purpose in this study is to evaluate therapeutic effects of stellate ganglion block (SGB) Botulinum Toxin on referactory facial nerve palsy

详细描述

:Idiopathic facial nerve palsy (Bell's palsy) is caused by damage to the facial nerve at any site of the peripheral branches after the facial nucleus.Stellate ganglion block is inteneded to increase blood flow and promotes nerve regeneration. the local stellate ganglion block with bupivacaine and corticosteroid treatment for acute peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local therapy may be necessary and some time may ve ineffective. Our purpose in this study is to evaluate therapeutic effects of stellate ganglion block (SGB) Botulinum Toxin on referactory facial nerve palsy

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed by clinical and neurological assessment as one-sided idiopathic facial palsy
  • Age 18 to 60 •-ASA i-II

排除标准

  • Exclusion Criteria:
  • coagulation dysfunction
  • mental or cognitive dysfunclion
  • allergy to injected medication

研究组 & 干预措施

Botulinum Toxin

Active Comparator

injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)

干预措施: Botox (Drug)

steroid

Active Comparator

injected 10 mL of 0.25% bupivacaine with triamcinolonacetonide 4 mg/ml

干预措施: triamcinolonacetonide (Drug)

结局指标

主要结局

Change from Baseline House-Brackmann

时间窗: : Baseline ,change from baseline House-Brackmann at 7th day,one month,two month, three month

Change from Baseline House-Brackmann

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Emad Zarief , MD

professor

Assiut University

研究点 (1)

Loading locations...

相似试验